Pricing Disclosures

To view state-required pricing disclosures, please log in to Merck Connect.

To view state-required pricing disclosures, please click on your state.

  • Pursuant to Colorado law, HB 19-1131, Merck is required to provide to Colorado prescribers pricing information about certain Merck products, as well as the names of generic products in the same therapeutic class. The generic products listed are not necessarily the generic form of the Merck product. Rather, these drugs could be the generic form of a non-Merck drug in the same therapeutic class. The generic products listed are not necessarily interchangeable with the Merck product, nor should they be implied to have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

    The prices listed reflect Merck’s Wholesale Acquisition Costs for the Merck product. The prices paid by consumers may vary from the prices listed.

    • BELSOMRA® (suvorexant) tablets, for oral use, C-IV Pricing PDF
    • DELSTRIGO™ doravirine/lamivudine/tenofovir disoproxil fumarate 100 mg/300 mg/300 mg tablets Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B. Pricing PDF
    • DIFICID® (fidaxomicin) tablets, for oral use Pricing PDF
    • ISENTRESS® (raltegravir) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir) film-coated tablets, for oral use Pricing PDF
    • JANUMET® (sitagliptin and metformin HCl) tablets and JANUMET® XR (sitagliptin and metformin HCl extended-release) tablets Before prescribing JANUMET or JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis. Pricing PDF
    • JANUVIA® (sitagliptin) tablets Pricing PDF
    • NOXAFIL® (posaconazole) injection, for intravenous use; delayed-release tablets, for oral use; oral suspension Pricing PDF
    • PIFELTRO™ doravirine 100 mg tablets Pricing PDF
    • PREVYMIS™ (letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL Pricing PDF
    • SEGLUROMET™ (ertugliflozin and metformin HCI) Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis. Pricing PDF
    • SIVEXTRO® (tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use Pricing PDF
    • STEGLATRO™ (ertugliflozin) 5 mg, 15 mg tablets Pricing PDF
    • STEGLUJAN™ (ertugliflozin and sitagliptin) Pricing PDF

    Alliance Products*

    *These products are co-developed and co-commercialized with another manufacturer.

    **LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

    ***LYNPARZA® is a registered trademark of the AstraZeneca group of companies.

  • Pursuant to Vermont’s Pharmaceutical Marketer Price Disclosure Law, 18 V.S.A. § 4633, Merck is required to provide to Vermont prescribers pricing information about certain Merck products, as well as other products in the same therapeutic class. The “other products” listed are not necessarily interchangeable with the Merck product, nor should they be implied to have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

    Further, as required by Vermont law, the prices listed are derived from Average Wholesale Price, which is provided by a third party publisher. The prices paid by consumers may vary from the prices listed.

    View Pricing Disclosures
US-IMA-0046008/19